Press release
Exomes Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Exomes Pipeline Report to explore emerging therapies, key Exomes Companies, and future Exomes treatment landscapes @ Exomes Pipeline Outlook Report [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Exomes Pipeline Report
* DelveInsight's Exomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exomes treatment.
* The leading Exomes Companies such as Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 andothers.
* Promising Exomes Therapies such as CAP-1002, EXO-CD24, AGLE-102, Progenza, EV-101 , andothers.
Discover how the Exomes treatment paradigm is evolving. Access DelveInsight's in-depth Exomes Pipeline Analysis for a closer look at promising breakthroughs @ Exomes Clinical Trials and Studies [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Exomes Emerging Drugs Profile
* CAP-1002: Capricor Therapeutics
Capricor's (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor's scientific founder, Dr. Eduardo Marban. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration.
* EXO-CD24: Nano24
EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage-from pathogen-associated molecular patterns (DAMPs and PAMPs) therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx Trademark cells. Exosomes displaying murine CD24 (mCD24) were also created.
* AGLE-102: Aegle Therapeutics
AGLE 102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.
* Progenza: Cambium Bio
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing.
* EV-101: EV Therapeutics
EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.
Get a detailed analysis of the latest innovations in the Exomes pipeline. Explore DelveInsight's expert-driven report today! @ Exomes Unmet Needs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Exomes Companies
Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.
Exomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Exomes Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Exomes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Exomes Pipeline Report
* Coverage- Global
* Exomes Companies- Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24 and others.
* Exomes Therapies- CAP-1002, EXO-CD24, AGLE-102, Progenza, EV-101 , and others.
* Exomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Exomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Exomes drug development? Find out in DelveInsight's exclusive Exomes Pipeline Report-access it now! @ Exomes Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Exosomes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Exosomes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CAP-1002: Capricor Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EXO-CD24: Nano24
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Progenza: Cambium Bio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EV-101: EV Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Exosomes Key Companies
* Exosomes Key Products
* Exosomes - Unmet Needs
* Exosomes - Market Drivers and Barriers
* Exosomes - Future Perspectives and Conclusion
* Exosomes Analyst Views
* Exosomes Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exomes-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dyspepsia-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exomes Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3855032 • Views: …
More Releases from ABNewswire
Hypoparathyroidism Pipeline 2025: Therapies Under Investigation, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoparathyroidism pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypoparathyroidism treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypoparathyroidism Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoparathyroidism Market.
The Hypoparathyroidism Pipeline report embraces in-depth commercial and clinical…
D-Thrive Powers Businesses and Agencies with SEO, WordPress Design, and White-La …
D-Thrive, founded by Shivem Aggarwal in Amritsar, India, is a digital marketing company offering SEO, WordPress design, and white-label marketing services. With a focus on affordability, transparency, and innovation, D-Thrive supports local businesses in India and global agencies with fast delivery, measurable results, and outsourcing solutions that scale.
D-Thrive is changing the way businesses and agencies approach digital growth by offering SEO, WordPress design, and white-label marketing services under one roof.…
HER2-Negative Metastatic Breast Cancer Market Positioned for Accelerated Develop …
The Key HER2-Negative Metastatic Breast Cancer Companies in the market include - Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.
DelveInsight's "HER2-Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the HER2-Negative Metastatic…
Getek Launches ACU Portable Air Clean Unit for Industrial, Commercial, and Clean …
Beyond HEPA: Refillable Molecular Air Cleaning for Targeted AMC and VOC Removal
Tainan, Taiwan - August 28th, 2025 - GE Technology Inc. (Getek) announces the launch of the ACU portable air clean unit. ACU combines high-efficiency particulate control with customizable molecular filtration in a self-contained mobile unit, offering a solution for indoor air quality and controlled-environment contamination control in both commercial and industrial settings.
Engineered for Beyond-HEPA and Targeted Molecular Control
Unlike conventional…
More Releases for Exomes
Rising Cancer Prevalence Driving Growth In The Next-Generation Sequencing Data A …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Next-Generation Sequencing Data Analysis Market Size By 2025?
The market size for next-generation sequencing data analysis has experienced immense growth recently. Its valuation is projected to rise from $1.21 billion in 2024 to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trend Reshaping the Next-Generation Sequencing Data Analysis Market in 2025: …
How Are the key drivers contributing to the expansion of the next-generation sequencing data analysis market?
The rising incidence of cancer is anticipated to spike the expansion of the next-generation sequencing data analysis market. Cancer is a set of diseases defined by the unregulated proliferation and distribution of abnormal cells within the body, potentially leading to severe health issues or death if left untreated. Unhealthy lifestyle choices, such as smoking, heavy…
Next-Generation Sequencing Data Analysis Market Forecast 2025-2034: Evaluating G …
What Is the Forecasted Market Size and Growth Rate for the Next-Generation Sequencing Data Analysis Market?
The market size of next-generation sequencing data analysis has seen a substantial surge in recent times. It is projected to elevate from $1.21 billion in 2024 to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of 22.0%. The growth witnessed during the historic period can be traced back to its increasing application…
Next-Generation Sequencing Data Analysis Market Share, Trends, Size, Major Playe …
The Business Research Company recently released a comprehensive report on the Global Next-Generation Sequencing Data Analysis Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Caviar Biotec Introduces Groundbreaking Animal-Friendly Caviar Exosomes for Skin …
Caviar Biotec announces the launch of a groundbreaking animal-friendly caviar exosome technology that promises to revolutionize the skincare industry. Utilizing advanced stem cell technology, these caviar exosomes are derived in a sustainable and ethical manner, ensuring no harm to animals.
The patented caviar stem cell technology involves lysing stem cells to extract and release exosomes ensuring the capture of all bioactive molecules essential for superior skincare.
Caviar exosomes offer a new cosmetic…
Technological Developments to Augment Global Molecular Forensic Market Growth
According to a new market research report launched by Inkwood Research, the Global Molecular Forensic Market is expected to grow with a CAGR of 9.31% in terms of revenue, reaching a revenue of $950.1 million by 2032.
Browse 84 Market Data Tables and 66 Figures spread over 180 Pages, along with an in-depth analysis of the Global Molecular Forensic Market by Technology, Product, Application, End-User, & Geography.
Refer to the Report…
